Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Study of Sodium Oligo-mannurarate (GV-971) Capsule on Mild to Moderate Alzheimer Disease

NCT02293915 is registered in ClinicalTrials.gov with Shanghai Greenvalley Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT02293915
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02293915 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Study of Sodium Oligo-mannurarate (GV-971) Capsule on Mild to Moderate Alzheimer Disease
Lead sponsor
Shanghai Greenvalley Pharmaceutical Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
April 1, 2014
Completion date
September 28, 2018
Enrollment
818 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

cognitive impairment, mild to moderate alzheimer disease